Abstract
Background Aspirin resistance, as determined by measuring platelet aggregation function, has been investigated as a proxy outcome for clinical treatment failure with low-dose aspirin (occurrence of cardiovascular events despite regular aspirin intake). However, among adults with cardiovascular disease (CVD), there is no method to predict aspirin treatment failure using routinely available clinical data. We aimed to develop and internally validate the Vascular Intervention Stratification Tool for Aspirin (VISTA), a model that predicts inter-individual variability in clinical response to low-dose aspirin.
Methods We used electronic health records of the Hong Kong Hospital Authority to identify derivation (n=48,743) and validation (n=322,731) cohorts consisting of individuals diagnosed with CVD between January 1, 2015 to December 31, 2018. The composite outcome of recurrent CVD event included the diagnosis of coronary heart disease, ischemic stroke, and peripheral artery disease after low-dose aspirin initiation (≤ 100 mg). Cox proportional hazards regression with the least absolute shrinkage and selection operator regularization was used to identify the most strongly associated and relevant risk factors for aspirin treatment failure. One-year hazard ratio (HR) was estimated across different risk categories for aspirin treated vs. untreated individuals.
Results The derivation cohort included 1,623 individuals who initiated low-dose aspirin after their CVD diagnosis. Among 109 variables available, six were selected as model inputs: atrial fibrillation, dyslipidemia, hyperglycemia, polypharmacy, neutrophilia, and elevated serum creatine kinase. In the model validation cohort, we identified 22,192 individuals who initiated low-dose aspirin and 3,747 individuals without aspirin, other antiplatelets, or anticoagulants. Results of the model validation demonstrated a strong graded association between the number of VISTA risk factors and the one-year risk of CVD. Compared to untreated individuals, low-dose aspirin use with no VISTA risk factors had the lowest HR for CVD (0.68, 95% CI of 0.57 to 0.81). For low-dose aspirin user with 1-2 VISTA risk factors, HRs was 0.87 (0.81 to 0.93). The presence of 3-6 VISTA risk factors was associated with aspirin treatment failure (HR 0.99; 95% CI of 0.88 to 1.12), which occurred in approximately 20% of patients in our validation cohort.
Conclusions VISTA can predict the heterogeneity of low-dose aspirin’s treatment effect against recurrent CVD. VISTA could be used to stratify patients based on six readily available risk factors and inform patients and clinicians about the potential benefits of aspirin therapy and the potential for alternate antiplatelet treatments.
What is new?
We developed VISTA (Vascular Intervention Stratification Tool for Aspirin), the first tool that enables the stratification of low-dose aspirin treatment effect for the secondary prevention of cardiovascular disease (CVD). By utilizing six easily accessible clinical risk factors (atrial fibrillation, dyslipidemia, hyperglycemia, polypharmacy, neutrophilia, and elevated serum creatine kinase), VISTA allows for the assessment of aspirin suitability before prescription.
VISTA can differentiate patients who are likely to benefit significantly from aspirin treatment (0 risk factors, hazard ratio [HR] of 0.68) from those who may experience aspirin treatment failure (3-6 risk factors, HR of 0.99).
What are the clinical implications?
Estimated from a high-quality contemporary validation cohort, there are approximately 20% of patients with CVD who may experience aspirin treatment failure.
By utilizing VISTA, healthcare providers can personalize aspirin treatment, optimizing its effectiveness and minimizing the potential for treatment failure. This tool empowers clinicians to make more accurate and tailored decisions in prescribing low-dose aspirin for secondary prevention of cardiovascular disease, ultimately leading to improved patient outcomes.
Competing Interest Statement
EWYC reports honorarium from Hospital Authority; and grants from Research Grants Council (RGC, Hong Kong), Research Fund Secretariat of the Food and Health Bureau, National Natural Science Fund of China, Wellcome Trust, Bayer, Bristol-Myers Squibb, Pfizer, Janssen, Amgen, Takeda, and Narcotics Division of the Security Bureau of the Hong Kong Special Administrative Region, outside the submitted work. CSLC has received grants from the Food and Health Bureau of the Hong Kong Government, Hong Kong Research Grant Council, Hong Kong Innovation and Technology Commission, Pfizer, IQVIA, MSD, and Amgen; and personal fees from PrimeVigilance; outside the submitted work. RL has received grants from Hong Kong Research Grant Council, Hong Kong Innovation and Technology Commission; and research donations from Oxford Nanopore Technologies, outside the submitted work. All other authors declare no competing interests.
Funding Statement
Nil.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethical approval for this study was granted by the Institutional Review Board of The University of Hong Kong/HA Hong Kong West Cluster (UW24-124).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
↵* Co-first authors
Data Availability
Data will not be available for others as the data custodians have not given permission.
